The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).
Alex Delaney-Gesing
Advertisement
Articles by Alex Delaney-Gesing
Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.
Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.
Advertisement
Latest Updated Articles
Gyroscope Therapeutics, UPenn to develop gene therapies for serious eye diseasesPublished: January 10th 2021 | Updated:
Neurophth and AAVnerGene partner on AAV capsids for next-gen ophthalmic gene therapyPublished: January 19th 2021 | Updated:
MeiraGTx announces Fast Track designation by FDA for gene therapy candidate to treat ACHMPublished: January 26th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
Quarter Century Update: Platform Approaches and Industry Investment
5
